Aurora Announces Distribution Partnership with Leafio Australia

Rhea-AI Summary

Aurora (NASDAQ: ACB) announced on December 2, 2025 that its subsidiary MedReleaf Australia has signed a distribution partnership with Leafio, the wholesale arm of Montu Australia. The agreement appoints Leafio as a wholesaler for Aurora's medical cannabis brands MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed and will distribute TGA‑GMP certified products through Leafio's nationwide supply chain.

The arrangement will support clinician education and clinical support for prescribers, and enable distribution to a network that services over 4,000 pharmacies across Australia, aiming to expand patient access and research collaboration.

Positive

• Nationwide reach via a supply chain servicing over 4,000 pharmacies
• Multiple brands included: MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., IndiMed
• TGA-GMP certified products for Australian medical channels
• Clinical support and clinician education included in partnership

Negative

• None.

Insights

Commercial Partnerships Analyst

Distribution deal expands Aurora's Australian reach to 4,000 pharmacies, improving patient access and clinician support.

Aurora Cannabis and Leafio formed a distribution partnership announced on Dec. 2, 2025. Leafio will wholesale Aurora's MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co. and IndiMed medical products through a nationwide supply chain serving over 4,000 pharmacies. The products are described as TGA-GMP certified and the agreement includes clinician education and clinical support.

The business mechanism is straightforward: Leafio provides wholesale logistics and pharmacy reach, while Aurora supplies certified medical products and clinical support. This arrangement should increase product availability through established medical channels and scale patient access without new manufacturing steps.

Key dependencies and risks include successful onboarding of products into Leafio's distribution network, acceptance by pharmacies and prescribers, and operational execution of clinician education. The announcement cites education and clinical support, which matter for uptake, but provides no enrollment or sales targets.

Watch pharmacy roll-out progress and any statements about formulary placements, prescriber engagement metrics, or monthly distribution volumes over the next 6–12 months. Confirm TGA-GMP status in documentation and track whether the partnership yields measurable increases in patient access through Leafio's channel.

The collaboration will improve medical cannabis access and better serve patients across Australia

NASDAQ | TSX: ACB

EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfolio of medical cannabis products under the MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co. and IndiMed brands.

"We are excited to join forces with Leafio to improve access to consistent, high-quality medical cannabis for Australian patients," says Stanley Sack, Interim Managing Director of MedReleaf Australia. "Our TGA-GMP certified products combined with Leafio's extensive sector knowledge and focus on clinician education, makes us ideal partners as we continue to grow our leadership in this important market."

"Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world-class products and expertise," said Nicole Le Maistre, General Manager of Leafio. "This partnership will deliver meaningful benefits to the region's medical cannabis industry, from enhanced research and product innovation to trusted education and improved patient outcomes."

Under the agreement, Aurora's premium medical cannabis products will be distributed through Leafio's nationwide supply chain, which services over 4,000 pharmacies. For further information about medical cannabis products, doctors and healthcare professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

About Leafio

Leafio works directly with thousands of pharmacies all across the country, providing them with a comprehensive range of medical cannabis brands and products. Aiming to provide medications on-demand and on time, its east coast-based warehouses dispatch every day of the week to a network of more than 4,000 pharmacies around Australia. leafio.com.au

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's distribution partnership with Leafio Australia and the associated benefits, including enhanced research, product innovation, educational opportunities, enhanced patient access and improved patient outcomes, and statements regarding expectations for continued growth in the Australian market.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-announces-distribution-partnership-with-leafio-australia-302629402.html

SOURCE Aurora Cannabis Inc.

FAQ

What did Aurora (ACB) announce on December 2, 2025 about Australia?

Aurora announced MedReleaf Australia signed a distribution partnership with Leafio to expand medical cannabis distribution across Australia.

Which Aurora brands will Leafio distribute in Australia under the ACB partnership?

Leafio will distribute MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed brands.

How many pharmacies does Leafio's supply chain service for Aurora (ACB) products?

Leafio's nationwide supply chain services over 4,000 pharmacies in Australia.

Are Aurora's Australian products covered by any quality certification in the ACB partnership?

Yes, the products are described as TGA‑GMP certified for the Australian market.

What support will clinicians get from the Aurora (ACB) and Leafio partnership?

The agreement includes clinician education and access to MedReleaf Australia's clinical support team for doctors and healthcare professionals.